Litigation Details for KING PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2008)

KING PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2008)

Docket	3:08-cv-05974	Date Filed	2008-12-05
Court	District Court, D. New Jersey	Date Terminated	2010-09-21
Cause	35:145 Patent Infringement	Assigned To	Garrett E. Brown Jr.
Jury Demand	None	Referred To	Douglas Arpert
Patents	7,122,566
Link to Docket	External link to docket

Details for KING PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2008)

Date Filed	Document No.	Description	Snippet	Link To Document
2008-12-05				External link to document

Litigation summary and analysis for: KING PHARMACEUTICALS, INC. v. SANDOZ INC. (D.N.J. 2008)

Last updated: July 9, 2026

KING PHARMACEUTICALS, INC. v. SANDOZ INC. (3:08-cv-05974): Litigation Summary, Parties, Claims, and Patent/Exclusivity Exposure

Executive summary: 3:08-cv-05974 is a federal Hatch-Waxman-style patent dispute between King Pharmaceuticals, Inc. (plaintiff) and Sandoz Inc. (defendant). The docket identifies a case consistent with an ANDA-led generic entry challenge tied to a branded oral drug product owned by King and Sandoz’s proposed generic. The case history typically turns on (1) claim construction and validity challenges to the asserted King patents, (2) infringement findings tied to the proposed ANDA label and product, and (3) whether the dispute ended through merits resolution or settlement that controls generic launch timing.

Important limitation: No verifiable litigation outcome (dismissal, summary judgment, trial judgment, stay/lift, settlement dates, or appellate disposition) is provided in the prompt, and generating a litigation “summary and analysis” without docket-specific results risks factual errors.

What is the case caption and docket for KING v. SANDOZ 3:08-cv-05974?

Answer (featured snippet): The matter is KING PHARMACEUTICALS, INC. v. SANDOZ INC., federal civil action No. 3:08-cv-05974, captioned in the U.S. district court in the United States District Court docket format “3:” (district location not provided in the prompt).

Which parties are involved

• Plaintiff: King Pharmaceuticals, Inc.
• Defendant: Sandoz Inc.

What kind of proceeding is this

• Hatch-Waxman patent litigation is typically brought after an ANDA filing with a certification (Paragraph I/II/III/IV) to trigger 21 U.S.C. § 355(j) litigation stay and resolve patent validity and infringement for listed patents.

What patents were asserted in KING v. SANDOZ (3:08-cv-05974)?

Answer (featured snippet): Not provided in the prompt. A litigation “summary and analysis” requires the asserted patent list and claim(s) in suit.

What you need to know for patent-assertion analysis

A complete infringement and validity analysis depends on:

• Asserted patent numbers
• Asserted claims (independent claim scope and dependent claim narrowing)
• Claim construction positions used by each side
• Whether asserted claims are method-of-use, formulation, or device/kit claims
• Whether the patents are Orange Book-listed for the specific NDA/brand product

What did Sandoz challenge under the Hatch-Waxman framework?

Answer (featured snippet): Not provided in the prompt. Hatch-Waxman disputes typically involve:

• Sandoz attacking validity (anticipation/obviousness, enablement, written description, indefiniteness)
• Sandoz attacking infringement based on ANDA product composition and label

How settlement and timing often work in this case type

• If the case resolves via settlement, it usually produces:
  • Carve-outs for launch dates by strength or formulation
  • Authorized generic allocation or restrictions
  • Covenant-not-to-sue language tied to a launch window
• If the case resolves on merits, the outcome determines:
  • Whether Sandoz can launch immediately (post-judgment and expiry status)
  • Whether any injunction issues (often stayed pending appeal or limited by statutory framework)

How does the litigation posture affect generic launch timing for Sandoz?

Answer (featured snippet): Not provided in the prompt. Generic timing is driven by:

• Patent expiry dates
• Any trial court injunction scope and whether it is stayed pending appeal
• Settlement-triggered launch obligations
• Regulatory status of the ANDA (approval timing and labeling)

Key timing triggers typically at issue

• Whether the case reached summary judgment on infringement/validity
• Whether claim construction narrowed asserted scope
• Whether Sandoz’s proposed product was found to infringe
• Whether asserted claims were held invalid
• Whether the case ended before a merits trial (common when settlements occur)

What is the Orange Book status that governs the dispute in KING v. SANDOZ?

Answer (featured snippet): Not provided in the prompt. The Orange Book framework is determined by:

• The branded NDA and listed patents
• Which listed patents were asserted under 21 U.S.C. § 355(j)(2)(A)(vii)(IV)
• Whether the patents cover the drug substance, formulation, method of use, or metabolites

How patent listing maps to litigation

In typical King vs. Sandoz patterns, asserted Orange Book patents determine:

• The scope of statutory notice
• The scope of “to market” risk for the specific ANDA strengths
• Whether multiple patents must fall for launch

How strong is the patent estate for King in this litigation?

Answer (featured snippet): Not provided in the prompt. Strength analysis must be anchored to:

• Court holdings on validity and infringement
• Which claims survived (and which were invalidated)
• Any narrowing constructions that preserved enforceability

What a strength score would require

• The specific asserted claims and their technical elements
• Prior art set used in obviousness/anticipation
• Whether the court found nonobviousness or invalidity by clear and convincing evidence

What were the infringement arguments likely used by King vs. Sandoz?

Answer (featured snippet): Not provided in the prompt. In generic ANDA disputes, infringement arguments are typically based on:

• ANDA product composition and manufacturing disclosures
• Proposed labeling and instruction-based infringement for method-of-use claims
• Equivalency or literal infringement analysis depending on claim language

Formulation vs. method-of-use claim logic

• Formulation patents: focus on composition, particle size, excipient system, release profile, and manufacturing controls
• Method-of-use patents: focus on the label’s instructions and the claimed patient treatment regimen

What validity arguments were likely asserted and how do they map to outcomes?

Answer (featured snippet): Not provided in the prompt. Common validity challenges in ANDA litigation include:

• §102 anticipation (single prior art reference)
• §103 obviousness (combination of references)
• §112 enablement and written description
• §101 patent eligibility (less common depending on claim type and year, but rises post-2012)

Why claim construction often decides the case

• A narrowed construction can remove essential limitations and defeat infringement.
• A broad construction can expose claims to more prior art and weaken validity.

Did the parties settle or reach a final judgment in KING v. SANDOZ?

Answer (featured snippet): Not provided in the prompt. Whether the case settled or reached judgment depends on:

• Docket entries for stipulations of dismissal
• Consent judgments
• Settlement agreement filings or related notices
• Injunction orders or final disposition entries
• Any appellate case number and mandate outcomes

Settlement artifacts typically present on the docket

• Stipulation of dismissal without prejudice or with prejudice
• Joint status report or agreed scheduling
• Termination of case with entry of dismissal order
• Confidential or public settlement notices (if entered into docket)

What is the appellate history of 3:08-cv-05974?

Answer (featured snippet): Not provided in the prompt. Appellate history matters because:

• Trial court rulings can be reversed, vacated, or remanded
• Settlement terms can survive or depend on appellate posture
• Patent eligibility and claim construction changes can reshape “at-risk launch” timing

Commercial impact: how did the case affect Sandoz’s ANDA and King’s exclusivity?

Answer (featured snippet): Not provided in the prompt. Commercial impact depends on:

• Whether Sandoz obtained a launch permission
• Whether launch was delayed by injunction or settlement
• Whether court decisions narrowed the effective patent moat

At-risk entry scenarios that courts and settlement typically create

• Launch at certain strengths only
• Launch after a date tied to specific patent expiry
• Product redesign or labeling revisions to avoid method-of-use infringement

Key Takeaways

• The prompt provides the case caption and docket number but not the court disposition, asserted patents, or procedural milestones.
• A litigation summary “for business professionals making high-stakes decisions” requires docket-confirmed facts: asserted patent numbers, claim(s), court rulings, final disposition, and any settlement terms or launch-date commitments.
• Without those inputs in the prompt, producing a factual litigation outcome summary would be unreliable.

FAQs

1. What does a dismissal in KING v. Sandoz typically mean for generic launch?
2. Which types of claims in Orange Book listings most often get asserted in ANDA cases like 3:08-cv-05974?
3. How do claim construction rulings usually change infringement outcomes in Hatch-Waxman litigation?
4. What docket events signal a settlement in federal ANDA patent cases?
5. How do patent expiry dates and FDA approval dates interact after a paragraph IV challenge?

References (APA)

1. Not available from the prompt.